<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00885937</url>
  </required_header>
  <id_info>
    <org_study_id>13941</org_study_id>
    <secondary_id>2008-008138-36</secondary_id>
    <secondary_id>Sinecort</secondary_id>
    <nct_id>NCT00885937</nct_id>
  </id_info>
  <brief_title>Comparative Safety Study of New Sinecort Formulation Versus Positive Control</brief_title>
  <official_title>Single-blind, Randomized, Controlled, Single Center Trial to Evaluate the Skin Irritation Potential of a New Topical Formulation by Means of an Occlusive Patch Test in Healthy Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is focused to prove a favorable safety profile of the new formulation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Irritation rate</measure>
    <time_frame>After 21 applications</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Irritation potential</measure>
    <time_frame>After 21 applications</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexpanthenol (Sinecort, BAY81-2996)</intervention_name>
    <description>1 squeeze of Sinecort cream sufficient to cover the area of the application chamber, (=50 mikro liter)</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Positive control, Na-laurylsulfat-solution</intervention_name>
    <description>50 mikro liter of 0.5 % Sodium-laurylsulfate-solution</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Untreated skin under application chamber</intervention_name>
    <description>Application of treatment chamber as in arm 1 and arm 2 on untreated skin</description>
    <arm_group_label>Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age of at least 18 years

          -  Skin type I, II, or III according to Fitzpatrick

          -  Subjects of childbearing potential must use an acceptable method of contraception.
             Hormonal or oral contraceptive drugs, intra-uterine devices (IUD) and abstinence are
             considered acceptable methods of contraception.

        Exclusion Criteria:

          -  Clinical history suggestive of intolerance, allergies or idiosyncrasies to one of the
             products or the ingredients of the products including the patch.

          -  Known skin allergies.

          -  Dermatologic diseases that might interfere with the evaluation of test site reaction.

          -  Other(s), considered as important by the investigator (e.g. multiple birth marks in
             the test area, important hair growth in the test area, pigmented or extremely
             suntanned skin impairing visual assessment, tattoos in the test area.

          -  Topical use of any cosmetic preparation on the test areas within 5 days prior to Day 1
             (Start of Treatment) or during the trial

          -  Within 3 weeks prior to Day 1 and during the entire trial. Any systemic or topical
             medication likely to interfere with the trial purposes: e.g. immune-modulating therapy
             (e.g. corticosteroids, cytotoxics or immunosuppressants) and any dermatological
             medication (drug or medical device.

          -  Within 1 week prior to Day 1 and during the entire trial any medication with common
             effects on the perfusion of skin vessels (e.g. vasodilators or vasoconstrictors,
             ß-receptor blocking drugs, antihistamines) should not be used.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Münster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48155</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://www.bayerpharma.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here to find results for studies related to Bayer Healthcare products.</description>
  </link>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2009</study_first_submitted>
  <study_first_submitted_qc>April 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2009</study_first_posted>
  <last_update_submitted>June 20, 2014</last_update_submitted>
  <last_update_submitted_qc>June 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dexpanthenol</keyword>
  <keyword>Safety,</keyword>
  <keyword>New formulation</keyword>
  <keyword>Topical administration</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

